Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients (OCTAVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02028117
Recruitment Status : Recruiting
First Posted : January 6, 2014
Last Update Posted : February 26, 2019
Sponsor:
Information provided by (Responsible Party):
PsiOxus Therapeutics Ltd

Brief Summary:
This study is a Phase I / Dose Expansion open label clinical study in patients with platinum-resistant epithelial ovarian cancer. The Phase Ia part of the study will determine the dose of enadenotucirev to be recommended for further studies and will examine primarily the safety and tolerability but also the pharmacokinetics of administering enadenotucirev intraperitoneally. In Phase Ib, the safety and tolerability and the pharmacokinetics of administering enadenotucirev intravenously in combination with weekly paclitaxel will be determined. The Dose Expansion Phase will begin as an open label dose expansion of that regimen and aims to determine whether intravenous enadenotucirev in combination with weekly paclitaxel has a risk benefit profile that supports further investigation in the treatment of patients with platinum-resistant epithelial ovarian cancer.

Condition or disease Intervention/treatment Phase
Recurrent Platinum Resistant Ovarian Cancer Biological: Enadenotucirev Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Clinical Study Of Enadenotucirev: Dose Finding and Proof of Concept in Platinum-Resistant Epithelial Ovarian Cancer.
Actual Study Start Date : June 2014
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : November 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ovarian Cancer

Arm Intervention/treatment
Experimental: Enadenotucirev Biological: Enadenotucirev
Oncolytic Virus




Primary Outcome Measures :
  1. Phase I - maximum tolerated dose [ Time Frame: Up to day 50 (post first dose) ]
    The maximally-tolerated dose (MTD) and/or the dose of enadenotucirev recommended for further studies of enadenotucirev when administered as monotherapy by IP injection or as combination therapy by IV infusion with weekly paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Able and willing to provide written informed consent and to comply with the study protocol
  2. Age ≥ 18 years
  3. Histologically confirmed non-resectable epithelial ovarian, fallopian tube or primary peritoneal cancer
  4. Phase Ia and Phase Ib (first 3 patients):

    Confirmed relapsed within the platinum-resistant time frame.

    • Platinum-resistance is defined as progression within 6 months of receiving prior platinum-containing chemotherapy, with progression identified either by CT scanning (RECIST v1.1) or symptomatic CA-125 progression (GCIG CA-125 criteria)
    • The treatment immediately prior to study entry need not be platinum-based OR Absence of other available treatment option

    Phase Ib (after first 3 patients) and Dose Expansion Phase:

    Confirmed relapsed within the platinum-resistant time frame

    • Platinum-resistance is defined as progression within 6 months of receiving prior platinum-containing chemotherapy, with progression identified either by CT scanning (RECIST v1.1) or symptomatic CA-125 progression (GCIG CA-125 criteria)
    • The treatment immediately prior to study entry need not be platinum-based

    Phase Ia and Phase Ib (first 3 patients):

    Evaluable disease (by RECIST v1.1).

    Phase Ib (after first 3 patients) and Dose Expansion Phase:

    Measurable disease (by RECIST v1.1)

  5. Able to undergo IP injection, including all administration procedures e.g. placement of IP catheter, iatrogenic ascites and ascites drainage and comply with study procedures in the Investigator's opinion (only required for patients scheduled for IP administration)
  6. Recovered to at least grade 1 from the effects (excluding alopecia) of any prior therapy for their malignancy at time of first administration of enadenotucirev
  7. ECOG Performance Status Score of 0 - 1
  8. Non-impaired renal function

    • Creatinine ≤1.5 mg/dl and estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73m2 (or measured creatinine clearance ≥60 ml/min)

  9. Urine dipstick for proteinuria at screening and baseline negative or trace. Patients may be included with results of 1+ if they have a spot urinary albumin:creatinine ratio (ACR) of either (i) ≤3 mg/mmol or (ii) >3 mg - <70 mg/mmol with a 24 hour urinary protein <0.2 g/24hours Adequate hepatic function

    • Serum bilirubin <1.5 x upper limit of normal (ULN)
    • Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3 x ULN
  10. Adequate bone marrow function:

    • Absolute neutrophil count (ANC) ≥1.5 x 109/l
    • Platelets ≥100 x 109/l
    • Haemoglobin ≥90 g/l
  11. Adequate coagulation tests: INR ≤1.5 x ULN;
  12. [Criterion has been removed in the current version of the protocol]
  13. For females of childbearing potential, a negative pregnancy test must be documented prior to enrolment
  14. For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception, including at least one method with a failure rate of < 1% per year (e.g. hormonal implants, combined oral contraceptives, vasectomised partner), during the treatment period and for at least 3 months after the last dose of study drug
  15. For selected patients in the Phase Ia and Dose Expansion Phase part of the study participating in the exploratory assessment of tumour samples:

    • Disease amenable to percutaneous image-guided biopsy.

  16. Normal serum complement (C3/C4)

Exclusion Criteria:

Patients who meet any of the following criteria are not eligible for enrolment:

  1. Tumours of malignant mixed mesodermal (MMMT) or mucinous subtypes, or non-epithelial ovarian cancers (e.g. Brenner tumours, Sex-cord tumours)
  2. [Criterion 2 has been removed in the current version of the protocol]
  3. Symptomatic sub-acute bowel obstruction, characterised by e.g. regular bloating, nausea, vomiting, constipation or diarrhoea
  4. Pregnant or lactating (nursing) women
  5. Known and/or a history or evidence of significant immunodeficiency due to underlying illness (e.g. human immunodeficiency virus [HIV]/acquired immunodeficiency syndrome [AIDS]) and/or medication (e.g. systemic corticosteroids at doses higher than dexamethasone 20 mg [or other corticosteroid equivalent to dexamethasone dose] for 14 days or prolonged administration [>14 days] of dexamethasone at doses higher than 10 mg but 20 mg [or other corticosteroid equivalent to dexamethasone dose] or other immunosuppressive medications including cyclosporine, azathioprine, interferons, within the past 14 days)
  6. Complete splenectomy
  7. Prior allogeneic or autologous bone marrow or organ transplantation
  8. Active infections requiring antibiotics, physician monitoring, or recurrent fevers >38.0 degrees centigrade associated with a clinical diagnosis of active infection
  9. Active viral disease, positive serology for HIV, hepatitis B or hepatitis C
  10. Use of the following anti-viral agents:

    • Ribavirin, adefovir, lamivudine or cidofovir within 7 days prior to day 1
    • or pegylated interferon (PEG-IFN) (within 14 days prior to day 1)
  11. Administration of an investigational drug within 28 days
  12. Concurrent administration of any cancer therapy other than planned study treatment
  13. Major surgery within 2 weeks prior to first dose of enadenotucirev
  14. Phase Ib (after first 3 patients) and Dose Expansion Phase only: another primary malignancy within the past 3 years (except for non-melanoma skin cancer or cervical cancer in situ or in situ stage 1 synchronous endometrial cancer)
  15. Symptomatic central nervous system (CNS) metastasis
  16. Inflammatory diseases of the bowel
  17. Concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/IV cardiac disease
  18. Any condition or illness that, in the opinion of the Investigator or the medical monitor, would compromise patient safety or interfere with the evaluation of the safety of the drug
  19. Known allergy to treatment medication or its excipients
  20. Any other medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.
  21. Any history of renal disease or renal injury or autoimmune disease. Patients with active, known or suspected auto-immune disease or a syndrome that requires systemic or immunosuppressive agents; patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune disease only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur in the absence of an external trigger are permitted to enrol providing they comply with the other eligibility criteria relating to renal function)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02028117


Contacts
Layout table for location contacts
Contact: PsiOxus Therapeutics enquiries@psioxus.com

Locations
Layout table for location information
Spain
Hospital Universitari de Girona Dr. Josep Trueta Recruiting
Girona, Spain, 17007
Contact: Maria Barrentina, MD    +34 972 225828    mpbarretina@iconcologia.net   
Clara Campal Comprehensive Cancer Center Hospital Recruiting
Madrid, Spain
Contact: Jesus Garcia-Donas, MD       jgarciadonas@hmhospitales.com   
MD Anderson Cancer Center Recruiting
Madrid, Spain
Contact: Antonio González Martin, MD       agonzalezm@seom.org   
Contact       covidal@mdanderson.es   
START MADRID-FJD, Hospital Fundación Jiménez Díaz Recruiting
Madrid, Spain
Contact: Victor Moreno, MD       Victor.Moreno@start.stoh.com   
Hospital Miguel Servet Recruiting
Zaragoza, Spain, 50009
Contact: Antón Antonio, MD    0034 976 765 500    aantont@gmail.com   
Contact: Concepción Velázquez    +34 976 765 500 5362    cvelazquez.miguelservet@gmail.com   
United Kingdom
The Royal Surrey County Hospital Active, not recruiting
Guildford, Surrey, United Kingdom, GU2 7WG
Beatson Institute Recruiting
Glasgow, United Kingdom, G61 1BD
Contact: Patricia Roxburgh, MD    0141 330 3968    patricia.roxburgh@glasgow.ac.uk   
Principal Investigator: Iain McNeish, MD         
The Christie Hospital Recruiting
Manchester, United Kingdom, M20 4BX
Contact: Gordon Jayson, MD       gordon.jayson2@christie.nhs.uk   
Principal Investigator: Gordon Jayson, MD         
Sponsors and Collaborators
PsiOxus Therapeutics Ltd

Layout table for additonal information
Responsible Party: PsiOxus Therapeutics Ltd
ClinicalTrials.gov Identifier: NCT02028117     History of Changes
Other Study ID Numbers: ColoAd1-2001
First Posted: January 6, 2014    Key Record Dates
Last Update Posted: February 26, 2019
Last Verified: February 2019

Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type